Not available
Quote | InflaRx N.V. (NASDAQ:IFRX)
Last: | $1.36 |
---|---|
Change Percent: | -0.74% |
Open: | $1.37 |
Close: | $1.36 |
High: | $1.45 |
Low: | $1.33 |
Volume: | 71,453 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | InflaRx N.V. (NASDAQ:IFRX)
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupt...
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor INF904 INF904 development will be initially targeted at chronic spontaneous urticaria (C...
Message Board Posts | InflaRx N.V. (NASDAQ:IFRX)
Subject | By | Source | When |
---|---|---|---|
Closing of offering, here comes first stop $6.25 | Gator44 | investorshub | 04/18/2023 2:25:38 PM |
$IFRX should go slowly 5$ + | frans | investorshub | 04/17/2023 6:53:22 PM |
$IFRX 4.2 now slowly on the move | frans | investorshub | 04/17/2023 4:47:27 PM |
in here at 4.10 | frans | investorshub | 04/17/2023 4:30:35 PM |
Still in downtrend and they will keep diluting | the_stockoracle | investorshub | 04/13/2023 4:10:45 PM |
News, Short Squeeze, Breakout and More Instantly...
InflaRx N.V. Company Name:
IFRX Stock Symbol:
NASDAQ Market:
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biotechnology company pioneering anti-inflammatory therapeutics ...
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupt...
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobe...